Last reviewed · How we verify
Lidocaine/tetracaine patch
Lidocaine and tetracaine are local anesthetics that block sodium channels in nerve fibers, preventing pain signal transmission at the site of application.
Lidocaine and tetracaine are local anesthetics that block sodium channels in nerve fibers, preventing pain signal transmission at the site of application. Used for Topical anesthesia for minor surgical procedures, Dermatological procedures requiring local anesthesia.
At a glance
| Generic name | Lidocaine/tetracaine patch |
|---|---|
| Also known as | Synera patch, Ralydan, Rapydan, Synera, 76667213 |
| Sponsor | East Carolina University |
| Drug class | Local anesthetic combination |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Both lidocaine and tetracaine work by inhibiting voltage-gated sodium channels in sensory nerve endings, which prevents depolarization and conduction of pain signals. The combination patch delivers both agents transdermally to provide rapid local anesthesia. This dual-agent formulation is designed to provide faster onset and more effective topical anesthesia compared to single-agent products.
Approved indications
- Topical anesthesia for minor surgical procedures
- Dermatological procedures requiring local anesthesia
Common side effects
- Skin irritation or erythema at application site
- Allergic contact dermatitis
- Systemic toxicity (rare with topical use)
Key clinical trials
- Effectiveness of Nitrous Oxide 50% for Reducing Pain and Distress Associated with Needle-stick in Children (NA)
- Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids (NA)
- Synera Venipuncture Pain (PHASE2)
- The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children (PHASE2)
- Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (PHASE4)
- Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias (PHASE4)
- Combining Placing a Synera Patch With Propofol/Lidocaine Mixture to Decrease Pain With IV Propofol Injection (PHASE4)
- Needle Procedures Success Rate After Application of Ralydan vs EMLA in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine/tetracaine patch CI brief — competitive landscape report
- Lidocaine/tetracaine patch updates RSS · CI watch RSS
- East Carolina University portfolio CI